

SYNOPSIS

<u>NAME OF SPONSOR/COMPANY:</u> Ortho Biotech Clinical Affairs, LLC.	<u>INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER</u>	<u>(FOR NATIONAL AUTHORITY USE ONLY)</u>
<u>NAME OF FINISHED PRODUCT:</u> Procrit	N/A	N/A
<u>NAME OF ACTIVE INGREDIENT(S):</u> Epoetin Alfa		
Protocol No.: PR03-19-057		
Title of Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Procrit® (Epoetin alfa) on Short-Term Outcomes in Orthopedic Subjects Undergoing Primary Unilateral Knee Arthroplasty		
Study Initiation/Completion Dates: 2 March 2005 (FPI) / 6 October 2005 (LPO)	Phase of development: II	
Objectives: To compare the effect of perioperative administration of Procrit® to that of preoperative autologous donation on post-operative rehabilitation outcomes in subjects undergoing primary unilateral knee arthroplasty.		
Methodology: The ANCOVA method will be used to analyze the primary endpoint with baseline (preoperative day-21) FIM score as a covariate.		
Criteria for Evaluation: The change in composite FIM score from entry into an inpatient rehabilitation facility to discharge (i.e., discharge from the inpatient rehabilitation facility) or post-operative day +28 (if not discharged by post-operative day +28) divided by the length of stay (LOS) in the inpatient rehabilitation facility, denoted as $\Delta\text{FIM}/\text{LOS}$, or “rate of functional recovery”.		
SUMMARY - CONCLUSIONS		
<u>EFFICACY RESULTS:</u> This study was discontinued due to poor enrollment. Data analysis was not performed because only 6 subjects were enrolled.		
<u>SAFETY RESULTS:</u> No Serious Adverse Events were reported. No significant non-serious adverse events were reported.		

SYNOPSIS (CONTINUED)

<u>NAME OF SPONSOR/COMPANY:</u> OBCA LLC	<u>INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER</u> Volume:	<u>(FOR NATIONAL AUTHORITY USE ONLY)</u>
<u>NAME OF FINISHED PRODUCT:</u> Procrit	Page:	
<u>NAME OF ACTIVE INGREDIENT(S):</u> Epoetin Alfa		
<u>CONCLUSION:</u> No conclusions were drawn from this study due to small sample size of the study population.		
Date of the report: 05 April 2006		

Disclaimer

Information in this posting shall not be considered to be a claim for any marketed product. Some information in this posting may differ from, or not be included in, the approved labeling for the product. Please refer to the full prescribing information for indications and proper use of the product.